Exploring neurotherapeutic space: How many neurological drugs exist (or could exist)?

Journal of Pharmacy and Pharmacology

Volumn 63, Issue 1, 2011, Pages 136-139

  Weaver, Donald F ^a   Weaver, Colin A ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

bioinformatics; cheminformatics; molecular modelling; neurological drugs

Indexed keywords

ALPRAZOLAM; BUSPIRONE; CARBAMAZEPINE; CENTRAL NERVOUS SYSTEM AGENTS; CITALOPRAM; CLOBAZAM; CLONAZEPAM; DEXAMPHETAMINE; DONEPEZIL; ETHOSUXIMIDE; FLUOXETINE; GABAPENTIN; GALANTAMINE; LAMOTRIGINE; LORAZEPAM; MESUXIMIDE; METHYLPHENIDATE; OXCARBAZEPINE; PHENELZINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; RIVASTIGMINE; TOPIRAMATE; TRANYLCYPROMINE; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; VIGABATRIN;

ARTICLE; MOLECULAR MODEL; NEUROPHARMACOLOGY; PHYSICAL CHEMISTRY; STATISTICAL ANALYSIS;

BRAIN DISEASES; CENTRAL NERVOUS SYSTEM AGENTS; COMPUTATIONAL BIOLOGY; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MODELS, MOLECULAR; SMALL MOLECULE LIBRARIES;

EID: 78650401399     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2010.01161.x     Document Type: Article

References (17)

1. Gorse AD,. Diversity in medicinal chemistry space. Curr Top Med Chem 2006; 6: 3-18.
2. Bleicher KH, et al. I Hit and lead generation beyond high-throughput screening. Nat Rev Drug Discovery 2003; 2: 369-378.
3. Gasteiger J, et al. Neural networks as data mining tools in drug design. J Phys Org Chem 2003; 16: 232-245.
4. Allinger NL, et al. Molecular mechanics. J Amer Chem Soc 1989; 111: 8551-8556.
5. MOE. Montreal, Quebec, Canada: Chemical Computing Group Inc., 2005: 06.
6. Maple 10 Mathematics and Engineering Software Maplesoft A Division of Waterloo Maple Inc University of Waterloo, 2007.
7. Nogrady T, Weaver DF,. Medicinal Chemistry: A Molecular and Biochemical Approach, 3rd edn. New York: Oxford University Press, 2005: 9-24.
8. Lipinski CA,. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000; 44: 235-249.
9. Lipinski CA, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997; 23: 3-25.
10. Lipinski CA, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001; 46: 3-26.
11. Clark DE,. In silico prediction of blood-brain barrier permeation. Drug Discov Today 2003; 15: 927-933.
12. Crippen GM, Wildman SA,. Prediction of physicochemical parameters by atomic contributions. J Chem Inf Comput Sci 1999; 39: 868-873.
13. Goodwin JT, Clark DE,. In silico predictions of blood-brain barrier penetration considerations to 'keep in mind'. J Pharmacol Exp Ther 2005; 315: 477-483.
14. Bohacek RS, McMartin C,. Exploring the universe of molecules for new drugs. Nat Med 1995; 1: 177-178.
15. Bohacek RS, et al. The art and practice of structure-based drug design a molecular modelling approach. Med Res Rev 1996; 16: 3-50.
16. Fink T, Reymond JL,. Virtual exploration of the chemical universe up to 11 atoms of C, N, O, F: assembly of 26.4 million structures 110.9 million stereoisomers and analysis for new ring systems stereochemistry physicochemical properties compound classes and drug discovery. J Chem Inf Model 2007; 47: 342-353.
17. National Center for Biotechnology Information. The PubChem Project. Accessed 1 September 2009.